RGNX vs. RLAY, CRGX, KYTX, CGEM, MESO, IMTX, BCRX, CABA, HLVX, and NVAX
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Relay Therapeutics (RLAY), CARGO Therapeutics (CRGX), Kyverna Therapeutics (KYTX), Cullinan Oncology (CGEM), Mesoblast (MESO), Immatics (IMTX), BioCryst Pharmaceuticals (BCRX), Cabaletta Bio (CABA), HilleVax (HLVX), and Novavax (NVAX). These companies are all part of the "biological products, except diagnostic" industry.
Relay Therapeutics (NASDAQ:RLAY) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
REGENXBIO received 387 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 65.89% of users gave REGENXBIO an outperform vote while only 59.02% of users gave Relay Therapeutics an outperform vote.
REGENXBIO has higher revenue and earnings than Relay Therapeutics. REGENXBIO is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relay Therapeutics presently has a consensus price target of $26.00, suggesting a potential upside of 294.54%. REGENXBIO has a consensus price target of $38.45, suggesting a potential upside of 139.59%. Given REGENXBIO's stronger consensus rating and higher possible upside, equities research analysts clearly believe Relay Therapeutics is more favorable than REGENXBIO.
In the previous week, Relay Therapeutics had 9 more articles in the media than REGENXBIO. MarketBeat recorded 10 mentions for Relay Therapeutics and 1 mentions for REGENXBIO. Relay Therapeutics' average media sentiment score of 0.78 beat REGENXBIO's score of -0.19 indicating that REGENXBIO is being referred to more favorably in the news media.
97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 3.5% of Relay Therapeutics shares are owned by company insiders. Comparatively, 13.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Relay Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.
REGENXBIO has a net margin of -291.99% compared to REGENXBIO's net margin of -1,263.49%. REGENXBIO's return on equity of -42.43% beat Relay Therapeutics' return on equity.
Summary
Relay Therapeutics beats REGENXBIO on 10 of the 18 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
REGENXBIO Competitors List
Related Companies and Tools